Outsourcing-Pharma: FHI Clinical to support ACTT remdesivir trial for COVID-19

July 23, 2020
Claudia Christian, Senior Vice President, Clinical Operations at FHI Clinical, recently spoke with Jenni Spinner, editor for Outsourcing-Pharma, about the clinical services that FHI Clinical is providing to the Frederick National Laboratory for Cancer research (operated by Leidos Biomedical Research) for the ongoing Adaptive COVID-19 Treatment Trial (ACTT), an adaptive study allowing investigation of putative therapeutics for the treatment of COVID-19 in hospitalized adults. Claudia explained how FHI Clinical is a chosen partner because of existing solutions to support an emergency response:

Senior Vice President, Clinical Operations

“Specifically, during this outbreak, we have helped deploy a remote site selection and initiation training program. While our SMAs have carried out the majority of the site management activities, our field CRAs have joined in the virtual monitoring.”

Clinical services provided by FHI Clinical for the ACTT study include:

news archive

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022
The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Read more »

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022
FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Read more »

Share this post